Health Care

4480 posts

‘Meaningful reduction’: Avita achieves positive Cohealyx grafting study interim results

Avita Medical has unveiled a significant reduction in mean time to skin grafting in positive interim…
London

With osteo Phase 3 trial at 50% recruitment, Paradigm Bio inks partnership with University of London

Paradigm Biopharma (ASX:PAR) has this week hit two big items out the park: first of all, hitting 50% recruitment

Emyira ramps up national growth strategy with NSW recruitment campaign

Emyira has initiated a significant growth program with a targeted clinical workforce recruitment campaign underway in…

Investors will get interim results from Paradigm’s Phase III study in Q3 of this year

Paradigm Biopharma has officially passed a milestone that gives investors in the company a 'fast-track' path…

Radiopharm Theranostics doses first patient in prostate cancer clinical study

Radiopharm Theranostics has dosed the first patient in its phase one clinical trial of a potential…

Nexsen accelerates global rollout for StrepSure

Nexen’s StrepSure diagnostic platform has received initial backing from the US Food and Drug Administration (FDA).

Radiopharma player Cyclopharm secures multi-site agreement in the States

Cyclopharm has signed a further multi-site agreement with leading US academic health system operator Northwestern Memorial…
Hong Kong coastline drone shot

Paradigm Biopharma activates Hong Kong trial site for Phase III osteo trial for iPPS

Paradigm Biopharmaceuticals (ASX:PAR) has kicked off the screening process for participants with osteoarthritis ahead of the company’s Hong Kong-based
Doctor at SNT

Existing myleofibrosis drugs can make the condition worse. Syntara Ltd could be about to change that 

In the face of a new war crisis weighing heavily on both equities and economics alike, value hunters (both long- and short-term minded
3D model of a brain concept

Some 80% of people who develop Parkinson’s present with this sleep disorder first. Syntara’s treating it

Syntara has today added ~$2 million to its coffers – $1.7M to be exact – after…